What is William Blair’s Forecast for IQVIA FY2025 Earnings?

IQVIA Holdings Inc. (NYSE:IQV) – Equities researchers at William Blair raised their FY2025 earnings per share (EPS) estimates for IQVIA in a research note issued to investors on Wednesday, July 23rd. William Blair analyst M. Smock now forecasts that the medical research company will earn $10.78 per share for the year, up from their previous forecast of $10.60. William Blair has a “Outperform” rating on the stock. The consensus estimate for IQVIA’s current full-year earnings is $10.84 per share. William Blair also issued estimates for IQVIA’s Q4 2025 earnings at $3.17 EPS, Q1 2026 earnings at $2.73 EPS, Q2 2026 earnings at $2.81 EPS, Q3 2026 earnings at $3.01 EPS, Q4 2026 earnings at $3.50 EPS and FY2026 earnings at $12.05 EPS.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.64 earnings per share.

Several other equities analysts have also issued reports on IQV. Evercore ISI raised their price objective on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Wednesday, July 9th. Truist Financial raised their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. JPMorgan Chase & Co. dropped their price objective on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a report on Monday, May 19th. Hsbc Global Res downgraded shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Finally, Mizuho increased their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Seven equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $228.62.

IQVIA Stock Performance

Shares of IQV stock opened at $194.41 on Monday. The stock’s 50-day moving average is $159.17 and its two-hundred day moving average is $170.16. The firm has a market cap of $33.05 billion, a price-to-earnings ratio of 28.13, a PEG ratio of 2.17 and a beta of 1.30. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently modified their holdings of IQV. Sowell Financial Services LLC purchased a new position in shares of IQVIA during the 1st quarter worth approximately $305,000. Mather Group LLC. increased its stake in shares of IQVIA by 83.5% during the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after purchasing an additional 350 shares in the last quarter. Park Avenue Securities LLC increased its stake in shares of IQVIA by 40.4% during the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after purchasing an additional 1,562 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of IQVIA by 34.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock worth $2,338,000 after purchasing an additional 3,398 shares in the last quarter. Finally, Blair William & Co. IL increased its stake in shares of IQVIA by 42.0% during the 4th quarter. Blair William & Co. IL now owns 5,742 shares of the medical research company’s stock worth $1,128,000 after purchasing an additional 1,699 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.